159 related articles for article (PubMed ID: 26548631)
1. Transamniotic stem cell therapy (TRASCET) mitigates bowel damage in a model of gastroschisis.
Feng C; Graham CD; Connors JP; Brazzo J; Pan AH; Hamilton JR; Zurakowski D; Fauza DO
J Pediatr Surg; 2016 Jan; 51(1):56-61. PubMed ID: 26548631
[TBL] [Abstract][Full Text] [Related]
2. Transamniotic stem cell therapy (TRASCET) in a leporine model of gastroschisis.
Feng C; Graham CD; Shieh HF; Brazzo JA; Connors JP; Rohrer L; Papadakis A; Zurakowski D; Fauza DO
J Pediatr Surg; 2017 Jan; 52(1):30-34. PubMed ID: 27836365
[TBL] [Abstract][Full Text] [Related]
3. A comparison between placental and amniotic mesenchymal stem cells in transamniotic stem cell therapy for experimental gastroschisis.
Chalphin AV; Tracy SA; Lazow SP; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2020 Jan; 55(1):49-53. PubMed ID: 31711742
[TBL] [Abstract][Full Text] [Related]
4. Transamniotic stem cell therapy (TRASCET) in a rabbit model of spina bifida.
Shieh HF; Tracy SA; Hong CR; Chalphin AV; Ahmed A; Rohrer L; Zurakowski D; Fauza DO
J Pediatr Surg; 2019 Feb; 54(2):293-296. PubMed ID: 30518492
[TBL] [Abstract][Full Text] [Related]
5. A comparison between placental and amniotic mesenchymal stem cells for transamniotic stem cell therapy (TRASCET) in experimental spina bifida.
Feng C; D Graham C; Connors JP; Brazzo J; Zurakowski D; Fauza DO
J Pediatr Surg; 2016 Jun; 51(6):1010-3. PubMed ID: 27013425
[TBL] [Abstract][Full Text] [Related]
6. Donor mesenchymal stem cells home to maternal wounds after transamniotic stem cell therapy (TRASCET) in a rodent model.
Graham CD; Shieh HF; Brazzo JA; Zurakowski D; Fauza DO
J Pediatr Surg; 2017 Jun; 52(6):1006-1009. PubMed ID: 28363468
[TBL] [Abstract][Full Text] [Related]
7. Postnatal fate of donor mesenchymal stem cells after transamniotic stem cell therapy in a healthy model.
Tracy SA; Chalphin AV; Lazow SP; Kycia I; Finkelstein A; Chan C; Zurakowski D; Fauza DO
J Pediatr Surg; 2020 Jun; 55(6):1113-1116. PubMed ID: 32164983
[TBL] [Abstract][Full Text] [Related]
8. Donor mesenchymal stem cell kinetics after transamniotic stem cell therapy (TRASCET) in a rodent model of gastroschisis.
Chalphin AV; Tracy SA; Kycia I; Chan C; Finkelstein A; Zurakowski D; Fauza DO
J Pediatr Surg; 2020 Mar; 55(3):482-485. PubMed ID: 31813581
[TBL] [Abstract][Full Text] [Related]
9. Donor mesenchymal stem cell linetics after transamniotic stem cell therapy (TRASCET) for experimental spina bifida.
Shieh HF; Ahmed A; Rohrer L; Zurakowski D; Fauza DO
J Pediatr Surg; 2018 Jun; 53(6):1134-1136. PubMed ID: 29580785
[TBL] [Abstract][Full Text] [Related]
10. Transamniotic stem cell therapy (TRASCET) for intrauterine growth restriction (IUGR): A comparison between placental and amniotic fluid donor mesenchymal stem cells.
Whitlock AE; Moskowitzova K; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2023 Feb; 58(2):305-309. PubMed ID: 36372622
[TBL] [Abstract][Full Text] [Related]
11. Trans-amniotic stem cell therapy (TRASCET) minimizes Chiari-II malformation in experimental spina bifida.
Dionigi B; Brazzo JA; Ahmed A; Feng C; Wu Y; Zurakowski D; Fauza DO
J Pediatr Surg; 2015 Jun; 50(6):1037-41. PubMed ID: 25929798
[TBL] [Abstract][Full Text] [Related]
12. Partial or complete coverage of experimental spina bifida by simple intra-amniotic injection of concentrated amniotic mesenchymal stem cells.
Dionigi B; Ahmed A; Brazzo J; Connors JP; Zurakowski D; Fauza DO
J Pediatr Surg; 2015 Jan; 50(1):69-73. PubMed ID: 25598096
[TBL] [Abstract][Full Text] [Related]
13. Transamniotic stem cell therapy: a novel strategy for the prenatal management of congenital anomalies.
Fauza DO
Pediatr Res; 2018 Jan; 83(1-2):241-248. PubMed ID: 28915235
[TBL] [Abstract][Full Text] [Related]
14. Hematogenous Donor Cell Routing Pathway After Transamniotic Stem Cell Therapy.
Tracy SA; Chalphin AV; Kycia I; Chan C; Finkelstein A; Zurakowski D; Fauza DO
Stem Cells Dev; 2020 Jun; 29(12):755-760. PubMed ID: 32228172
[TBL] [Abstract][Full Text] [Related]
15. Congenital diaphragmatic hernia as a potential target for transamniotic stem cell therapy.
Chalphin AV; Tracy SA; Lazow SP; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2020 Feb; 55(2):249-252. PubMed ID: 31753611
[TBL] [Abstract][Full Text] [Related]
16. Transamniotic Stem Cell Therapy.
Lazow SP; Fauza DO
Adv Exp Med Biol; 2020; 1237():61-74. PubMed ID: 31302870
[TBL] [Abstract][Full Text] [Related]
17. Induction of fetal diuresis with intraamniotic furosemide injection reduces intestinal damage in a rat model of gastroschisis.
Hakguder G; Olguner M; Gürel D; Akgür FM; Flake AW
Eur J Pediatr Surg; 2011 May; 21(3):183-7. PubMed ID: 21341178
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of transamniotic stem cell therapy for spina bifida by genetic engineering of donor mesenchymal stem cells with an Fgf2 transgene.
Lazow SP; Labuz DF; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2021 Jun; 56(6):1226-1232. PubMed ID: 33771369
[TBL] [Abstract][Full Text] [Related]
19. Brain protection by transamniotic stem cell therapy (TRASCET) in a model of intrauterine growth restriction (IUGR).
Whitlock AE; Moskowitzova K; Labuz DF; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2023 Jan; 58(1):3-7. PubMed ID: 36344286
[TBL] [Abstract][Full Text] [Related]
20. Fetal bone marrow homing of donor mesenchymal stem cells after transamniotic stem cell therapy (TRASCET).
Shieh HF; Ahmed A; Tracy SA; Zurakowski D; Fauza DO
J Pediatr Surg; 2017 Oct; ():. PubMed ID: 29132800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
